The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Pulmonary Or Respiratory Drug Delivery Market Become By 2030 Compared To 2026?
The pulmonary or respiratory drug delivery market size has experienced robust growth in recent years. This market is projected to expand from $75.67 billion in 2025 to $82.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.7%. Historically, this expansion has been driven by factors such as increasing asthma and COPD prevalence, widespread adoption of inhalers, the proliferation of respiratory hospitals, advancements in aerosol technologies, and the broadening of homecare treatment options.
The pulmonary or respiratory drug delivery market is anticipated to show robust expansion in the upcoming years, with its size projected to reach $114.23 billion in 2030, advancing at a compound annual growth rate (CAGR) of 8.6%. This increase throughout the forecast period is attributable to an aging population, rising air pollution exposure, growth in digital inhalers, expansion of homecare settings, and increasing chronic respiratory conditions. Key developments expected during this period involve the rising adoption of inhalation-based drug delivery, increasing demand for home-based respiratory therapies, growing use of dry powder and metered dose inhalers, expansion of chronic respiratory disease management, and an increased focus on patient-friendly delivery devices.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
Which Major Factors Are Contributing To The Development Of The Pulmonary Or Respiratory Drug Delivery Market?
The expanding occurrence of pneumonia is anticipated to stimulate growth within the pulmonary or respiratory drug delivery market in the coming period. Pneumonia, a lung infection, inflames the air sacs, which can then become filled with fluid or pus, resulting in symptoms such as coughing, fever, and labored breathing. The increasing occurrence of pneumonia is driven by factors including aging populations, compromised immune systems, respiratory infections, atmospheric pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery offers assistance to pneumonia patients through the direct administration of medications, like antibiotics, bronchodilators, or anti-inflammatory agents, to the lungs. This method allows for more rapid and potent treatment, helping to relieve symptoms, decrease inflammation, eliminate infections, and enhance respiratory function, thereby improving recovery and averting complications. As an illustration, in December 2024, the UK-based clinical research news platform, Clinical Trials Arena, reported a 461% surge in hospital admissions for Mycoplasma pneumoniae between October 2023 and February 2024, escalating from 110 to 617 admissions. Specifically, 20.2% of pneumonia cases were identified in children aged 0 to 4 years, 25.4% in those aged 5 to 9 years, and 17.5% in the 10 to 14 years age bracket, accounting for 410 out of 650 total reported cases. Consequently, the growing incidence of pneumonia acts as a key driver for the pulmonary or respiratory drug delivery market.
Which Segment-Based Categories Are Covered In The Pulmonary Or Respiratory Drug Delivery Market?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
Which Trends Are Influencing The Expansion Of The Pulmonary Or Respiratory Drug Delivery Market?
Leading companies active in the pulmonary or respiratory drug delivery market are increasingly prioritizing technological advancements, particularly complex drug delivery systems aimed at improving treatment efficacy and patient compliance. These complex drug delivery systems are advanced technologies designed to enhance the targeted delivery and controlled release of therapeutic agents, leading to better drug efficacy and patient outcomes. As an illustration, in July 2023, Viatris Inc., a US-based healthcare company that manufactures generic and branded medicines, alongside Kindeva Drug Delivery L.P., a US-based company providing drug delivery services, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol sanctioned by the Food and Drug Administration, a US-based government agency. This product is the initial generic form of AstraZeneca’s Symbicort and operates as a metered-dose inhaler, combining budesonide and formoterol for addressing asthma and chronic obstructive pulmonary disease. It is offered in two strengths: 80 micrograms and 160 micrograms, each with 4.5 micrograms of formoterol.
Who Are The Major Companies Operating In The Pulmonary Or Respiratory Drug Delivery Market?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
Access The Complete Pulmonary Or Respiratory Drug Delivery Market Report:
Which Region Stands As The Largest Contributor To The Pulmonary Or Respiratory Drug Delivery Market?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Pulmonary Or Respiratory Drug Delivery Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2026, By The Business Research Company
Pulmonary Drug Delivery Devices Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Respiratory Disease Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model